New combo therapy aims to shrink rectal tumors and save organs
NCT ID NCT07596290
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two immunotherapy drugs to radiation therapy can better shrink advanced rectal cancer than standard chemoradiation. About 342 adults with a specific type of rectal cancer will be randomly assigned to one of three treatment groups. The goal is to see if the new approach leads to a complete disappearance of the tumor, potentially allowing patients to avoid surgery and keep their rectum.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can precision protons spare rectal cancer patients from harsh side effects?
- Could a single drug replace surgery for rectal cancer?
- Can adding chemo after radiation help older adults with rectal cancer avoid surgery?
- Can a common muscle relaxant make radiation deadlier for rectal cancer?
- Timing of chemo may boost rectal cancer remission
- Immunotherapy combo may boost rectal cancer treatment